What this means
This is a trial that is still signing up people, and no results have been posted yet. It will test which weekly doses of two drugs are safe and work, but it does not show if they help aging.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 55–89
- Where
- 1 site, including Wisconsin
The science
- Registered title
- Rapalog Pharmacology (RAP PAC) Study
- Trial ID
- NCT05949658 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Aging
- What is tested
- Sirolimus, Everolimus
- Sponsor
- University of Wisconsin, Madison
- Ages
- 55 Years to 89 Years
- Dates
- First posted Jul 18, 2023 · updated May 28, 2026
Registry summary
The objective of RAP PAC is to identify safe and effective weekly dose(s) for the mTOR inhibitors sirolimus and everolimus that intervene on the underlying fundamental biology of aging. Participants who are 55-89 years old that are free of overt chronic diseases will be assigned to either 6 weeks of sirolimus or everolimus (5 mg, 10 mg, or 15 mg once per week). The investigators will complete the everolimus arm first and then subsequently complete the sirolimus arm of the study. Total time on study would be up to 17 weeks to complete baseline and follow up visits.
Sites (1)
- University of Wisconsin, Madison, Wisconsin, United States